All data are based on the daily closing price as of July 5, 2024
a
Adimmune
4142.TW
0.88 USD
0.00
0.00%
Overview
Last close
0.88 usd
Market cap
369.87M usd
52 week high
1.45 usd
52 week low
0.78 usd
Target price
1.08 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
6.2692
Price/Book Value
2.0442
Enterprise Value
383.93M usd
EV/Revenue
6.6376
EV/EBITDA
-23.1226
Key financials
Revenue TTM
51.23M usd
Gross Profit TTM
14.33M usd
EBITDA TTM
-14.26M usd
Earnings per Share
-0.04 usd
Dividend
N/A usd
Total assets
293.02M usd
Net debt
3.20M usd
About
Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is headquartered in Taichung, Taiwan.